Abstract
Background: Hypertrophic scar (HS) is a fibrotic cutaneous disease with few effective therapies. Lycorine is a drug with pro-apoptotic ability and anti-fibrosis potential. This study aimed to test whether lycorine could trigger the apoptosis of hypertrophic scar fibroblasts (HSFs) to inhibit HS formation.
Methods: The proapoptotic and anti-fibrosis effects of lycorine on the viability and apoptosis of human primary HSFs and their reactive oxygen species (ROS) production as well as a rabbit ear model of HS were determined by CCK-8, flow cytometry, Western blot, immunofluorescence, transwell migration, collagen gel contraction assays.
Results: Lycorine treatment selectively decreased the viability of HSFs, and induced their apoptosis, but not normal fibroblasts (NFs). Lycorine treatment increased the relative levels of Bax and cleaved PARP expression, cytochrome C cytoplasm translocation, but decreased Bcl-2, caspase-3 and caspase-9 expression, the mitochondrial membrane potential (MMP) in HSFs. Lycorine inhibited the migration and contraction of HSFs, and reduced the expression of collagen I, collagen III and α-SMA. Mechanistically, lycorine treatment stimulated high levels of ROS production, leading to apoptosis of HSFs while treatment with NAC, a ROS inhibitor, significantly mitigated or abrogated the pro-apoptotic and antifibrotic activity of lycorine in HSFs. Moreover, lycorine treatment mitigated the severity of HS in rabbit ears by inducing fibroblast apoptosis.
Conclusion: These results indicate that lycorine has a potent anti-fibrotic activity and is a potential drug for intervention of HS.
Introduction
Hypertrophic scar (HS) is a fibrotic disease and particularly affects the appearance and function of the skin (). Generally, various cutaneous injuries, such as burns, trauma and skin surgery, may cause pathological scarring of the dermis (). At present, non-surgical treatment for HS includes laser therapy, compression therapy, silicone, injection with corticosteroids, however, these therapeutic strategies are limited (; ; ). Hence, the development of new anti-scar therapies is necessary.
Mechanistically, HS is mainly caused by two factors, the continuous proliferation of dermal myofibroblasts and excessive deposition of extracellular matrix (ECM), such as collagen fibers in scar tissue (). After skin injury, many proliferating fibroblasts participate in tissue repair and secrete high levels of α-smooth muscle actin (α-SMA) and collagens, transforming to the myofibroblast phenotype (). Of note, α-SMA can enhance the contraction ability of HSFs, while collagen accumulation in ECM can lead to scar hardening, protruding skin surface, and the joint scar can cause limb contracture deformity (). Therefore, the inhibition of myofibroblast formation and decrease in fibrogenic factors, such as collagen, α-SMA, will be important to limit scar formation following a skin wounding.
The proliferating HSFs usually ignore apoptosis triggers. Accordingly, selective triggering HSF apoptosis may be a valuable strategy for intervention of HS (; ). Lycorine is a kind of natural alkaloid extracted from medicinal plants in the lycoris family (). Previous studies have shown that lycorine can inhibit the proliferation of various types of cancer cells (; ) and induce the apoptosis of human hepatoblastoma HepG2 and breast cancer MCF-7 cells (; ). In addition, lycorine has been used as a novel natural compound for the treatment of cardiac fibrosis () and alleviates the bleomycin-induced pulmonary fibrosis in rodents (). However, there is no information on the roles of lycorine in skin fibrosis.
Based on its proapoptotic ability and anti-fibrosis effect, this study tested the hypothesis that treatment with lycorine could ameliorate HS in human primary skin fibroblasts and a rabbit model of HS.
Materials and Methods
Cell Culture
The skin tissues were obtained from 17 volunteers, including 12 HS patients (6 female, 6 male, age 20–39 years), who were diagnosed pathologically, and five non-HS subjects (three males and two females, ages 18–29 years). Briefly, the dermal portion of scar tissues or normal skin tissues were cut into small pieces (1 mm3) and digested with collagenase type II (S10054, 0.8 mg/ml, Yuanye, China) at 37°C for 6–8 h (). The generating HS fibroblasts (HSFs) and normal fibroblasts (NFs) were cultured in DMEM medium (Gbico, United States) supplemented with 10% fetal bovine serum (FBS, Gbico) at 37°C in 5% CO2. The cells at passage 3–5 were used for following experiments.
Cell Viability Assay
HSFs and NFs (2 × 103cells/well) were cultured in 96-well plates overnight and treated in triplicate with different doses (0, 2.5, 5.0, 7.5, 10.0, 20.0, 30.0, 40.0 μmol/L) of lycorine (Glpbio, United States, GC38967) in dimethyl sulfoxide (DMSO, Sigma, United States) for 12–48 h. The cell viability was determined using a CCK8 kit (Fdbio, China, FD3788) per the manufacturer’s protocol.
Flow Cytometry Analysis of Cell Apoptosis
HSFs and NFs were cultured in 6-well plates overnight and treated in triplicate with vehicle or lycorine at 10, 20, and 40 μmol/L for 24 h. The cells were harvested and stained with Annexin V-FITC and propidium iodide (PI, 4abio, China) in the dark. After being washed, the frequency of apoptotic cells was analyzed by flow cytometry.
Western Blot Assay
HSFs were treated with vehicle or lycorine (10, 20, 40 μmol/L) for 24 h, harvested and lyzed in radioimmunoprecipitation assay (RIPA, Fdbio, FD008) buffer containing inhibitors of protease (Fdbio, FD1001) and phenylmethylsulfonyl fluoride (PMSF, Fdbio, China, FD0100), followed by centrifugation. The concentrations of lysate proteins were quantified using the BCA protein assay kit (Fdbio, FD 2001). The cell lysate samples (50 µg/lane) were separated by SDS-PAGE on 7.5%–12.5% gels and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Temecula, CA, United States). After being blocked with 5% non-fat dry milk in TBST buffer for 1 h, the membranes were incubated with primary antibodies at 4°C overnight. The bound antibodies were reacted with horseradish peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling Technology, #3108, #7076, 1:5000). Similarly, the collected ear tissues were homogenized and subjected to Western blot analysis. Mitochondrial proteins were extracted from each group of cells or tissues using the Cell Mitochondria Isolation Kit (Beyotime, China, C3601).
The primary antibodies were used at 1:1000 dilution, including Bax (CST, United States, #5023S), Bcl-2 (CST, #15071S), caspase9 (Proteintech, United States, 10380-1-AP), caspase3 (Proteintech, 19677-1-AP), PARP (Proteintech, 13371-1-AP), c-PARP (CST, #5625), anti-Cyt-c (Proteintech, 10993-1-AP), GAPDH (60004-1-Ig, 1:5000), anti-Cox-IV (CST, #4850), Collagen I (Proteintech, 14695-1-AP), Collagen III (Proteintech, 22734-1-AP), α-SMA (Proteintech, 14395-1-AP).
Mitochondrial Membrane Potential Assay
The impact of lycorine on mitochondrial membrane potential of HSFs was analyzed using JC1 (MCE, HY-15534, United States) staining. Briefly, HSFs were treated in triplicate with different doses of lycorine at 37°C for 24 or 48 h and stained with JC-1 for 15 min at 37°C in the dark. After being washed, the cells were analyzed under a fluorescence microscope (LSM880 Basic Operation, Zeiss, Germany).
Transwell Migration Assay
The HSFs were harvested and HSFs at 2 × 104 cells/well were cultured in FBS-free medium containing vehicle or 10, 20, and 40 μmol/L of lycorine in the upper chamber of 24-transwell plate. The bottom chambers were filled with 600 µl of medium containing 20% FBS. After being cultured for 24 h, the cells on the up-surface of chamber were removed using a cotton ball and the cells that had migrated onto the bottom surface of the chamber were fixed with paraformaldehyde for 30 min and stained with 0.1% crystal violet for another 30 min. The numbers of migrated cells in five visual fields ( × 100 magnification) were counted under a microscope in a blinded manner.
Collagen Gel Contraction Assay
HSFs (5 × 105 cells/mL, 2 ml) were mixed with rat tail collagen (900 μl, 5 mg/ml, Solarbi, China, C8062) and 10 × DMEM (100 μL) (pH ≈ 7) and cultured in 24-well plates (1 ml/well) in the presence of lycorine (10, 20, 40 μmol/L) or vehicle at 37°C for 30–60 min. The resulting collagen gel in each well was taken out and photoimaged at 12 or 48 h later. The changes in gel areas were calculated.
Immunofluorescence Staining
HSFs were cultured on glass coverslips in dishes overnight, and treated with different concentrations of lycorine for 24 h. The cells were fixed with 4% paraformaldehyde for 30 min, permeabilized with 0.25% of Triton-×100 for 20 min and blocked with goat serum for 1 h. The cells were incubated with primary antibodies overnight at 4°C. After being washed, the bound antibodies were reacted with fluorescent secondary antibodies at room temperature for 1 h and co-stained with DAPI. The fluorescent signals were captured under a confocal microscope (LSM880 Basic Operation, Zeiss, Germany). Similarly, rabbit ear scar tissue sections were fixed in 4% paraformaldehyde and subjected to immunofluorescence. The primary antibodies included Collagen I (Proteintech, 14695-1-AP), Collagen III (Proteintech, 22734-1-AP), caspase9 (Proteintech, 10380-1-AP).
Analysis of Reactive Oxygen Species
The impact of lycorine on ROS production in HSFs was determined by flow cytometry and immunofluorescence. Briefly, HSFs were treated in triplicate with vehicle or lycorine at 37°C for 24 h and after being washed, the cells were cultured in serum-free DMEM in the presence of 10 µM 2,7-dichlorofluorescein diacetate (DCFH-DA,APExBIO, Houston, TX, United States, C3890) at 37°C for 30 min in the dark. The cells were harvested for flow cytometry analysis in a Beckman Cyan flow cytometer (Beckman Coulter, Brea, CA, United States) and immunofluorescence analysis.
Real-Time Quantitative PCR
Total RNAs were extracted from scar tissue samples using RNA Easy Fast Tissue/Cell kit (TIANGEN, China) and reversely transcribed into cDNA using the Thermo Scientific RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, United States), according to the manufacturer s instructions. The relative levels of interesting gene mRNA transcripts to the control GAPDH were quantified by RT-qPCR using specific primers and SYBR Green PCR master mix (Toyobo, Osaka, Japan) on a Bio-Rad CFX96 Real Time PCR system (Bio-Rad, Hercules, CA, United States). The data were analyzed by 2
−ΔΔCt. The sequences of primers were used, according to a previous study (
):
Bcl-2-F: 5’ -GATTGTGGCCTTCTTTGAGTTC-3′
Bcl-2-R: 5’ -AAGTCTTCAGAGACACCCAGGA-3′
Bax-F: 5’ -TTTGCTTCAGGGTTTCATCC-3′
Bax-R: 5’ -GGCAGCGATCATCCTCTGTA-3′
GAPDH-F: 5’ -GAATCCACTGGCGTCTTCAC-3′
GAPDH-R: 5’ -CGTTGCTGACAATCTTGAGAGA-3′
A Rabbit Model of Ear Hypertrophic Scar
New Zealand white rabbits, weighing 2.0–2.5kg, were from Guangdong Medical Laboratory Animal Center (approval number: SCXK (yue) 2019–0035). All animal experimental protocols were approved by the Animal Experimental Center of the First Affiliated Hospital of Sun Yat-sen University. To establish a rabbit model of ear HS, the rabbits were anesthetized and the ventral surface of each ear was wounded with four 10-mm cylindrical cores (full-thickness and the perichondrium was preserved) using a 10-mm biopsy punch. After 14 days, the skin wound healed and scar was formed gradually. The rabbits were randomized and injected with 0.1 ml of vehicle or lycorine (5 mg/ml) into their ear scar region every 3 days (). The total duration of lycorine therapy was 14 days. At the end of the treatment (28 days post wounding), their scar tissues were dissected for histology, RT-qPCR and immunofluorescence analyses.
Histopathology
The dissected ear tissues were fixed in 10% of formalin overnight and paraffin-embedded. The tissue sections (5 µM) were regularly stained with hematoxylin and eosin or immunohistochemistry (IHC) staining. The stained tissue sections were photoimaged and observed under a light microscope. The primary antibodies were used at 1:200 for α-SMA (Proteintech, 14395-1-AP), 1:400 for Collagen I (Proteintech, 14695-1-AP), Collagen III (Proteintech, 22734-1-AP).
Statistical Analysis
The data are expressed as mean ± SEM. The difference between two groups was analyzed by the unpaired t-test analysis and the difference among multiple groups was analyzed by one-way ANOVA and post hoc Bonferroni’s correction using SPSS 24.0 software. A p-value of < 0.05 was considered statistically significant.
Results
Lycorine Decreases the Viability of Hypertrophic Scar Fibroblasts
To examine the direct effect of lycorine on cells viability, human NFs and HSFs were treated with lycorine at different concentrations (0, 10, 20, 40 µM) up to 48 h and their viabilities were determined by CCK-8 assays. As shown in Figure 1A, treatment with lycorine from 10 to 40 µM significantly decreased the viability of HSFs in a dose-dependent manner. Treatment with 20 µM lycorine for 48 h reduced the viability by>50%, similar to that of treatment with 40 µM lycorine for 24 h. The half maximal inhibitory concentration (IC50) of lycorine for HSFs with different duration were 43.63 µM (12 h), 34.54 µM (24 h), 25.16 µM (48 h), respectively. However, treatment with lycorine at the same dose ranges did not significantly alter the viability of NFs (Figure 1B). Hence, lycorine treatment selectively decreased the viability of HSFs in a dose and time-dependent manner.
FIGURE 1
Lycorine Increases the Intrinsic Apoptosis of Hypertrophic Scar Fibroblasts
Next, the effect of lycorine on fibroblast apoptosis was tested. NFs and HSFs were treated with different concentrations of lycorine for 24 h, the frequency of apoptotic cells was determined by flow cytometry (Figure 1C). Treatment with different doses of lycorine increased the percentages of apoptotic HSFs in a dose-dependent manner (Figure 1C). However, the same treatments did not significantly increase the percentages of apoptotic NFs in our experimental conditions (Figure 1D). Furthermore, Western blot uncovered that treatment with varying doses of lycorine significantly increased the relative levels of Bax, cleaved poly ADP-ribose polymerase (c-PARP), but gradually decreased Bcl-2, caspse-9 and caspase-3 as well as PARP expression in HSFs (Figure 1E).
To further confirm that lycorine acted through the intrinsic apoptotic pathway, the mitochondrial membrane potential (MMP) of individual groups of cells was measured by fluorescent imaging after staining the cells with JC-1. As shown in Figure 2A, compared with the cells treated with vehicle alone, treatment with different doses of lycorine reduced the contents of red mitochondrial aggregates, but enhanced green monomer signals in HSFs. Subsequently, treatment with varying doses of lycorine dose-dependently decreased the relative levels of mitochondrial cytochrome C, but increased cytoplasm cytochrome C, indicating that the decreased MMP by lycorine treatment promoted the release of cytochrome C from the mitochondria into the cytoplasm in HSFs (Figure 2B). However, there was no obvious alternation in the relative levels of Fas/FasL and caspase-8 expression in HSFs regardless of lycorine treatment, independent of death-receptor (Figure 2C). Together, lycorine treatment induced the apoptosis of HSFs through the mitochondrial apoptotic pathway.
FIGURE 2
Lycorine Reduces the Levels of Fibrosis in Hypertrophic Scar Fibroblasts
Besides hyperproliferation, the migration and contraction characteristics of myofibroblasts are also the main pathological features of HS. First, the characteristics of myofibroblasts in primary HSFs were examined. The relative levels of α-SMA, type I collagen and type III collagen in HSFs were significantly higher than that of NFs (Supplementary Figure S1A). Transwell migration assays unveiled that lycorine treatment significantly reduced the number of migrated cells (Figure 3A). Similarly, collagen gel contraction assays exhibited that lycorine treatment attenuated the contractile ability of HSFs (Figure3B).
FIGURE 3
Next, the anti-fibrosis ability of lycorine was examined. Both Western blot and immunofluorescence revealed that lycorine treatment dose-dependently decreased the relative levels of Collagen I and III, α-SMA expression in HSFs (Figures 3C,D). Collectively, these data indicated that lycorine treatment inhibited the profibrotic activity of HSFs.
Lycorine Stimulates High Levels of Reactive Oxygen Species Production, Leading to HSF Apoptosis
High levels of ROS can induce oxidative stress and cell apoptosis. To understanding the pharmacological action of lycorine, the effect of lycorine on ROS production was tested by fluorescent microscopy and flow cytometry. As shown in Figure 4A, treatment with varying doses of lycorine increased ROS levels in HSFs cells. A similar pattern of ROS levels was detected by flow cytometry (Figure 4B).
FIGURE 4
To determine the role of ROS in the lycorine-triggered HSF apoptosis, HSFs were treated with vehicle or lycorine in the presence or absence of 100 μM N-Acetylcysteine (NAC, a ROS inhibitor) () and the frequency of apoptotic HSFs was quantified by flow cytometry. First, the use of NAC alone or in combination with lycorine both can reduce the ROS level (Supplementary Figure S1B). Treatment with NAC alone did not alter the frequency of spontaneously apoptotic HSFs (Figure 4C). While treatment with 40 µM lycorine triggered 22.81% of apoptotic HSFs treatment with the same dose of lycorine, together with NAC, significantly mitigated the percentages of apoptotic HSFs to 5.21%. Furthermore, compared with lycorine alone, treatment with NAC decreased the levels of Bax and c-PARP, but increased Bcl-2, Caspase9, Caspase3, PARP expression in the lycorine-treated HSFs (Figure 4D). In addition, treatment with NAC also mitigated the decrease in the MMP and attenuated the translocation of Cyto-C from the mitochondria to the cytoplasm in HSFs (Figures 5A,B). Thus, lycorine stimulated high levels of ROS production, leading to HSF apoptosis.
FIGURE 5
Lycorine Treatment Alleviates Hypertrophic Scar of Rabbit Ears by Promoting Apoptosis in vivo
To test the effect of lycorine on HS in vivo, a rabbit ear model of HS was established by inducing four 10-mm cylindrical cores (full-thickness skin wounds) on the ventral side of each rabbit ear (Figure 6A). Two weeks later, when the wounds were healed (Figure 5B), the rabbits were randomized and injected subcutaneously with vehicle DMSO (control) or lycorine into the scars, followed by observation up to 28 days post the wounding. There were visible scars at 21 and 28 days post surgery (Figure 6B). While the scars were obviously prominent on the skin surface with darker color and harder texture in the control group of rabbits the scars in the lycorine-treated group appeared smoother, lighter and softer.
FIGURE 6
Histological analysis revealed that the scar thickness in the control group was significantly higher than that in the Lycorine-treated group at 28 days post surgery. While collagen fibers in the scar tissues of the control group exhibited disorder and rough, the collagen fibers in scar tissues of the lycorine-treated group were arranged in a neat and meticulous way (Figure 6C). The values of scar elevation index (SEI, a measure of the degree of HS) in the scar tissues of the lycorine-treated group were significantly less than that of the control group (Figure 6D).
Immunohistochemical results indicated that the levels of collagen I, collagen III and α-SMA in fibroblasts of scar tissues in the control group were significantly higher than that in the lycorine-treated group (Figure 6E). These suggest that lycorine may attenuate the conversion of fibroblasts to myofibroblast phenotype, contributing to its antifibrotic effect in vivo. Further RT-qPCR revealed that lycorine treatment increased the relative levels of Bax mRNA transcripts, but decreased Bcl-2 mRNA transcripts in rabbit ear scar tissues at 28 days post surgery (Figure 6F). Similarly, immunofluorescence displayed that the levels of caspase-9 expression in rabbit ear scar tissue sections from the lycorine-treated group were lower than that in the control group (Figure 6G). Therefore, lycorine treatment attenuated the severity of HS in rabbit ear by promoting fibroblast apoptosis in vivo.
Discussion
The results from this study indicated that lycorine reduced fibrotic activity of HS in two ways. Firstly, lycorine stimulated high levels of ROS production, which promoted the intrinsic apoptosis of HSFs and inhibited myofibroblast proliferation. Secondly, lycorine also inhibited the collagen and α-SMA expression in HSFs, reducing the accumulation of ECM. More importantly, treatment with lycorine significantly mitigated the severity of HS by enhancing the apoptosis of HSFs in a rabbit ear model, demonstrating its pro-apoptotic and anti-fibrosis activities in vivo. These novel findings suggest that lycorine may be a promising candidate for development of new therapies for HS.
Lycorine, an alkaloid extracted from Lycoris, has a variety of pharmacological effects, including anti-tumor (; ), anti-inflammatory (), antibactericidal activities and others (), which are associated with triggering cancer cell apoptosis and necroptosis and inhibiting their invasion and metastasis (; ; ). The data from this study indicated that lycorine treatment selectively decreased the viability of HSFs and triggered their apoptosis, but did not affect NFs, consistent with the results of previous studies (). These findings suggest that HSFs may have unique characteristics and like cancer cells, be sensitive to apoptotic stimulators induced by lycorine.
Apoptosis can be triggered by the intrinsic mitochondrial and extrinsic death receptor pathways. The intrinsic apoptotic pathway is mainly regulated by pro-apoptotic and anti-apoptotic members in the Bcl-2 protein family (). It is well known that anti-apoptotic Bcl-2 and Bcl-xl can support cell survival by inhibiting the activity of pro-apoptotic Bax and Bak while various endogenous apoptotic stimuli can up-regulate the expression of pro-apoptotic Bax and Bak, which translocate into the mitochondrial outer membrane and polymerize to form membrane channels to promote the release of Cyt-C from the mitochondria, leading to apoptosis (). In fact, lycorine can induce HepG2 cell apoptosis by enhancing cyt-C release form the mitochondria (). Similarly, we found that lycorine decreased the MMP of HSFs and increased cytoplasm cyt-C in HSFs besides the increased frequency of apoptotic HSFs. In the cytoplasm, the Cyt-C, together with caspases (mainly caspase 9) formed apoptotic bodies to drive a cascade of downstream caspases (mainly caspase 3), leading to cell apoptosis. Consistently, lycorine treatment decreased the relative levels of caspse-3, caspase-9 and PARP in HSFs, which may reflect an increase in the degradation of Caspse9, Caspase3 and PARP, similar to that in oral squamous cell carcinoma HSC-3 cells (). However, we did not find that lycorine treatment significantly modulated the levels of caspase-8, Fas and FasL expression in HSFs. These data were in disagreement with previous observations that lycorine induces the apoptosis of human osteosarcoma and breast cancer cells through the exogenous death receptor pathway (; ). Therefore, lycorine can trigger the apoptosis of varying types of pathogenic cells through different apoptotic pathways, dependent on the cell origination and state.
HSFs are different from NFs as HSFs have the characteristics of myofibroblast cells with high levels of α-SMA expression (). In this study, we extracted primary HSFs from human scar tissues and found that they were α-SMA (+) and had potent contractility, contributing to HS formation. In addition, the extracted primary HSFs, like myofibroblasts, also had aberrant migration and proliferation abilities and produced high levels of collagens (type III collagen was dominant in the early stage and type I collagen in the late stage) that might be deposited in the ECM, leading to HS formation. Because lycorine also has anti-fibrosis potential we investigated the effect of lycorine on major fibrosis factors. The data unveiled that lycorine treatment inhibited the migration and contraction of HSF, the expression of α-SMA, and the production of collagen I and collagen III, extending previous observation in colorectal cancer cells (). Therefore, our data support the notion that lycorine can attenuate myofibroblast phenotype.
Our data indicated that lycorine modulated mitochondrial homeostasis and induced the apoptosis of HSFs. Evidently, lycorine treatment decreased the MMP, which is an important indicator of oxidative stress (; ). Given that ROS levels are determinants of oxidative stress-related apoptosis or the changes in the MMP (; ), we examined the effect of lycorine on ROS production in HSFs. Similar to a previous report (), we found that lycorine treatment stimulated high levels of ROS production in HSFs and produced high levels of ROS appeared to be responsible for the pro-apoptotic and anti-fibrotic activities of lycorine. Supportively, treatment with NAC, a ROS scavenger (), alone did not affect the apoptosis of HSFs, but significantly mitigated or abrogated the pro-apoptotic and anti-fibrotic effects of lycorine in HSFs by increasing the MMP, reducing cytoplasm cyt-C translocation and apoptosis.
Finally, to explore the effect of lycorine on HS in vivo (), we established the most classical rabbit ear model of HS. We found that lycorine treatment mitigated the severity of HS by enhancing HSF apoptosis in a rabbit ear model of HS. Therefore, high levels of ROS induced by lycorine may be critical for its pharmacological actions in inhibiting HS formation.
Conclusion
In summary, our study indicated that lycorine stimulated the production of high levels of ROS to induce the apoptosis of HSFs through the intrinsic mitochondrial pathway, and reduce their migration and collagen contraction ability, as well as the accumulation of ECM (Figure 7). Similarly, lycorine treatment mitigated the severity of HS in vivo by enhancing the apoptosis of HSFs. Therefore, lycorine may be a promising drug for treatment of HS.
FIGURE 7
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.
Ethics statement
The studies involving human participants were reviewed and approved by the Ethics Committee for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-sen University. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by the Ethics Committee for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-sen University.
Author contributions
Conceptualization, YD, DL, ZZ, ZH, and BT; methodology, analysis, visualization and writing, YD, DL, and ZX; review and editing, YD, DL, and ZH; project administration and funding acquisition, BT. All authors have read and agreed to the published version of the manuscript.
Funding
This work was supported by the grants from the National Natural Science Foundation of China (No. 81871565, No. 82072181, No. 82172213) and the Sun Yat-sen University Clinical Research 5010 Program (No. 2018003).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fbioe.2022.892015/full#supplementary-material
Reference
1
BendaifH.MelhaouiA.RamdaniM.ElmsellemH.DouezC.El OuadiY. (2018). Antibacterial Activity and Virtual Screening by Molecular Docking of Lycorine from Pancratium Foetidum Pom (Moroccan Endemic Amaryllidaceae). Microb. Pathog.115, 138–145. 10.1016/j.micpath.2017.12.037
2
CadenasS. (2018). Mitochondrial Uncoupling, ROS Generation and Cardioprotection. Biochim. Biophys. Acta (BBA) - Bioenerg.1859 (9), 940–950. 10.1016/j.bbabio.2018.05.019
3
CaoZ.YangP.ZhouQ. (2013). Multiple Biological Functions and Pharmacological Effects of Lycorine. Sci. China Chem.56 (10), 1382–1391. 10.1007/s11426-013-4967-9
4
ChenM.LiuX.HuB.FanZ.SongY.WeiH.et al (2018). Rabbit Hemorrhagic Disease Virus Non-structural Protein 6 Induces Apoptosis in Rabbit Kidney Cells. Front. Microbiol.9, 3308. 10.3389/fmicb.2018.03308
5
DanialN. N. (2007). BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death. Clin. Cancer Res.13 (24), 7254–7263. 10.1158/1078-0432.ccr-07-1598
6
DemineS.RenardP.ArnouldT. (2019). Mitochondrial Uncoupling: A Key Controller of Biological Processes in Physiology and Diseases. Cells8 (8), 795. 10.3390/cells8080795
7
DingY.YuJ.ChenX.WangS.TuZ.ShenG.et al (2021). Dose‐Dependent Carbon‐Dot‐Induced ROS Promote Uveal Melanoma Cell Tumorigenicity via Activation of mTOR Signaling and Glutamine Metabolism. Adv. Sci.8 (8), 2002404. 10.1002/advs.202002404
8
FengY.WuJ.-J.SunZ.-L.LiuS.-Y.ZouM.-L.YuanZ.-D.et al (2020). Targeted Apoptosis of Myofibroblasts by Elesclomol Inhibits Hypertrophic Scar Formation. EBioMedicine54, 102715. 10.1016/j.ebiom.2020.102715
9
FinnertyC. C.JeschkeM. G.BranskiL. K.BarretJ. P.DziewulskiP.HerndonD. N. (2016). Hypertrophic Scarring: the Greatest Unmet Challenge after Burn Injury. Lancet388 (10052), 1427–1436. 10.1016/s0140-6736(16)31406-4
10
FritschM.GüntherS. D.SchwarzerR.AlbertM.-C.SchornF.WerthenbachJ. P.et al (2019). Caspase-8 Is the Molecular Switch for Apoptosis, Necroptosis and Pyroptosis. Nature575 (7784), 683–687. 10.1038/s41586-019-1770-6
11
GaoL.FengY.GeC.XuX.WangS.LiX.et al (2021). Identification of Molecular Anti-metastasis Mechanisms of Lycorine in Colorectal Cancer by RNA-Seq Analysis. Phytomedicine85, 153530. 10.1016/j.phymed.2021.153530
12
JiY.YuM.QiZ.CuiD.XinG.WangB.et al (2017). Study on Apoptosis Effect of Human Breast Cancer Cell MCF-7 Induced by Lycorine Hydrochloride via Death Receptor Pathway. Saudi Pharm. J.25 (4), 633–637. 10.1016/j.jsps.2017.04.036
13
KwanP. O.TredgetE. E. (2017). Biological Principles of Scar and Contracture. Hand Clin.33 (2), 277–292. 10.1016/j.hcl.2016.12.004
14
Lamoral-TheysD.AndolfiA.Van GoietsenovenG.CimminoA.Le CalvéB.WauthozN.et al (2009). Lycorine, the Main Phenanthridine Amaryllidaceae Alkaloid, Exhibits Significant Antitumor Activity in Cancer Cells that Display Resistance to Proapoptotic Stimuli: An Investigation of Structure−Activity Relationship and Mechanistic Insight. J. Med. Chem.52 (20), 6244–6256. 10.1021/jm901031h
15
LeeH. J.JangY. J. (2018). Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids. Int. J. Mol. Sci.19 (3), 711. 10.3390/ijms19030711
16
LiJ.WangJ.WangZ.XiaY.ZhouM.ZhongA.et al (2020). Experimental Models for Cutaneous Hypertrophic Scar Research. Wound Rep. Reg.28 (1), 126–144. 10.1111/wrr.12760
17
LiM.-H.LiaoX.LiC.WangT.-T.SunY.-S.YangK.et al (2021). Lycorine Hydrochloride Induces Reactive Oxygen Species-Mediated Apoptosis via the Mitochondrial Apoptotic Pathway and the JNK Signaling Pathway in the Oral Squamous Cell Carcinoma HSC-3 Cell Line. Oncol. Lett.21 (3), 236. 10.3892/ol.2021.12497
18
LiangQ.CaiW.ZhaoY.XuH.TangH.ChenD.et al (2020). Lycorine Ameliorates Bleomycin-Induced Pulmonary Fibrosis via Inhibiting NLRP3 Inflammasome Activation and Pyroptosis. Pharmacol. Res.158, 104884. 10.1016/j.phrs.2020.104884
19
LimandjajaG. C.NiessenF. B.ScheperR. J.GibbsS. (2021). Hypertrophic Scars and Keloids: Overview of the Evidence and Practical Guide for Differentiating between These Abnormal Scars. Exp. Dermatol.30 (1), 146–161. 10.1111/exd.14121
20
LiuW.-y.TangQ.ZhangQ.HuC.-p.HuangJ.-b.ShengF.-f.et al (2019). Lycorine Induces Mitochondria-dependent Apoptosis in Hepatoblastoma HepG2 Cells through ROCK1 Activation. Front. Pharmacol.10, 651. 10.3389/fphar.2019.00651
21
LopezJ.TaitS. W. G. (2015). Mitochondrial Apoptosis: Killing Cancer Using the Enemy within. Br. J. Cancer112 (6), 957–962. 10.1038/bjc.2015.85
22
LuoY.RoyM.XiaoX.SunS.LiangL.ChenH.et al (2015). Lycorine Induces Programmed Necrosis in the Multiple Myeloma Cell Line ARH-77. Tumor Biol.36 (4), 2937–2945. 10.1007/s13277-014-2924-7
23
ManuskiattiW.KaewkesA.YanC.NgJ.GlahnJ.WanitphakdeedechaR. (2021). Hypertrophic Scar Outcomes in Fractional Laser Monotherapy versus Fractional Laser-Assisted Topical Corticosteroid Delivery: A Randomized Clinical Trial. Acta Derm. Venereol.101 (3), adv00416. 10.2340/00015555-3781
24
NewtonK.WickliffeK. E.MaltzmanA.DuggerD. L.RejaR.ZhangY.et al (2019). Activity of Caspase-8 Determines Plasticity between Cell Death Pathways. Nature575 (7784), 679–682. 10.1038/s41586-019-1752-8
25
ParkG. S.AnM. K.YoonJ. H.ParkS. S.KohS. H.MauroT. M.et al (2019). Botulinum Toxin Type A Suppresses Pro-fibrotic Effects via the JNK Signaling Pathway in Hypertrophic Scar Fibroblasts. Arch. Dermatol Res.311 (10), 807–814. 10.1007/s00403-019-01975-0
26
RoyM.LiangL.XiaoX.FengP.YeM.LiuJ. (2018). Lycorine: A Prospective Natural Lead for Anticancer Drug Discovery. Biomed. Pharmacother.107, 615–624. 10.1016/j.biopha.2018.07.147
27
SassettiE.ClausenM. H.LaraiaL. (2021). Small-Molecule Inhibitors of Reactive Oxygen Species Production. J. Med. Chem.64 (9), 5252–5275. 10.1021/acs.jmedchem.0c01914
28
SchimmelK.JungM.FoinquinosA.JoséG. S.BeaumontJ.BockK.et al (2020). Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. Circulation141 (9), 751–767. 10.1161/circulationaha.119.042559
29
ShiF.CaoX.HuZ.MaD.GuoD.ZhangJ.et al (2017). Pleiotropic FTY720 Is a Specific and Potent Therapy for Hypertrophic Scars. J. Invest. Dermatol.137 (7), 1552–1561. 10.1016/j.jid.2017.02.978
30
ShinD.MinnK. W. (2004). The Effect of Myofibroblast on Contracture of Hypertrophic Scar. Plastic Reconstr. Surg.113 (2), 633–640. 10.1097/01.prs.0000101530.33096.5b
31
SinhaK.DasJ.PalP. B.SilP. C. (2013). Oxidative Stress: the Mitochondria-dependent and Mitochondria-independent Pathways of Apoptosis. Arch. Toxicol.87 (7), 1157–1180. 10.1007/s00204-013-1034-4
32
SuL. J.ZhangJ. H.GomezH.MuruganR.HongX.XuD.et al (2019). Reactive Oxygen Species-Induced Lipid Peroxidation in Apoptosis, Autophagy, and Ferroptosis. Oxid. Med. Cell. Longev.2019, 5080843. 10.1155/2019/5080843
33
TutuianuR.RoscaA. M.FloreaG.PrunăV.IacomiD. M.RădulescuL.A.et al (2019). Heterogeneity of Human Fibroblasts Isolated from Hypertrophic Scar. Rom. J. Morphol. Embryol.60 (3), 793–802. 10.1016/j.ijporl.2021.110709
34
WangJ.XuJ.XingG. (2017). Lycorine Inhibits the Growth and Metastasis of Breast Cancer through the Blockage of STAT3 Signaling Pathway. Acta Biochim. Biophys. Sin. (Shanghai).49 (9), 771–779. 10.1093/abbs/gmx076
35
WangG.HuangK.DongY.ChenS.ZhangJ.WangJ.et al (2018). Lycorine Suppresses Endplate-Chondrocyte Degeneration and Prevents Intervertebral Disc Degeneration by Inhibiting NF-Κb Signalling Pathway. Cell. Physiol. Biochem.45 (3), 1252–1269. 10.1159/000487457
36
ZhengZ.-G.ZhuS.-T.ChengH.-M.ZhangX.ChengG.ThuP. M.et al (2021). Discovery of a Potent SCAP Degrader that Ameliorates HFD-Induced Obesity, Hyperlipidemia and Insulin Resistance via an Autophagy-independent Lysosomal Pathway. Autophagy17 (7), 1592–1613. 10.1080/15548627.2020.1757955
37
ZhuZ.HouQ.LiM.FuX. (2020). Molecular Mechanism of Myofibroblast Formation and Strategies for Clinical Drugs Treatments in Hypertrophic Scars. J. Cell. Physiol.235 (5), 4109–4119. 10.1002/jcp.29302
Summary
Keywords
hypertrophic scar, lycorine, apoptosis, reactive oxygen species, fibrosis
Citation
Dong Y, Lv D, Zhao Z, Xu Z, Hu Z and Tang B (2022) Lycorine Inhibits Hypertrophic Scar Formation by Inducing ROS-Mediated Apoptosis. Front. Bioeng. Biotechnol. 10:892015. doi: 10.3389/fbioe.2022.892015
Received
08 March 2022
Accepted
06 May 2022
Published
24 May 2022
Volume
10 - 2022
Edited by
Taixing Cui, University of South Carolina, United States
Reviewed by
Rong Yin, Shanxi Medical University, China
Peng Zhao, Southern Medical University, China
Shi-hui Zhu, Second Military Medical University, China
Updates
Copyright
© 2022 Dong, Lv, Zhao, Xu, Hu and Tang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhicheng Hu, willway128@163.com; Bing Tang, tangbing@mail.sysu.edu.cn
† These authors have contributed equally to this work
This article was submitted to Biomaterials, a section of the journal Frontiers in Bioengineering and Biotechnology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.